Recent meta-analyses also suggest that GLP-1R agonists reduce kidney disease progression in individuals with T2DM or overweight/obesity regardless of chronic kidney disease (CKD) status and are associated with a lower incidence of all-cause mortality and major adverse kidney events in patients with T2DM and established CKD [23,24]. Here, GLP1R is linked to obesity disorder.